Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-12-01

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the effect of teriflunomide treatment on microglial activation in late stage multiple sclerosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis

NCT03134716

Multiple Sclerosis

ACTIVE_NOT_RECRUITING

Effect of Cladribine Treatment on Microglial Activation in the CNS

NCT04239820

Multiple Sclerosis

ACTIVE_NOT_RECRUITING

To Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis

NCT03856619

Relapsing Multiple Sclerosis

COMPLETED PHASE4

Multimodal Imaging of MS Reveals the Smoldering Inflammation

NCT04126772

Multiple Sclerosis

ACTIVE_NOT_RECRUITING

Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

NCT01403376

Multiple Sclerosis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In Multiple Sclerosis (MS), plaques in the white and grey matter of the brain represent the best known pathological changes of the disease, but a significant inflammation process has also been detected outside these plaques in connection with the disease. This extensive, diffuse inflammatory process correlates with the progression of the disease, measured by EDSS score (Expanded Disability Status Scale status) and reduction in patients' cognitive level. According to neuropathological research, the diffuse inflammatory process outside the plaques is connected with powerful activation of microglia, oxidative stress, and deficiencies in mitochondrial activity. The activation of microglial cells can be measured in vivo in patients using positron-emission tomography (PET) scanning and so-called TSPO radioligands, such as the 11C-PK11195 radioligand. 11C-PK11195 radioligand binds to TSPO molecules, which manifest on the surface of activated, but not un-activated, microglia.

Teriflunomide treatment is expected to slow down the process of increasing microglial activation. TSPO-PET imaging allows in vivo follow-up of the pathogenic process associated with the gradual MS disease evolution, and allows to evaluate whether teriflunomide treatment has an effect on disease progression-related pathology.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Teriflunomide group

20 MS patients who are using teriflunomide medication under the supervision of their treating neurologist.

No interventions assigned to this group

No disease modifying treatment

10 MS-patients who do not use any regular disease modifying MS treatment of their own volition

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signing the consent form
* Having used teriflunomide treatment for at least 6 months
* 40-55 years of age at the time of signing the research consent form
* MS diagnosis in accordance with either the Poser or McDonald criteria
* EDSS 2-6.5
* Clear lesion load in brain MRI (\> 9 T2 lesion)

Exclusion Criteria

* Patients suffering from another brain disease of in addition to multiple sclerosis
* Steroid treatment 4 weeks prior to the scan
* Significant pathology in the MRI scan other than MS-related lesions
* Patients suffering from claustrophobia or panic disorder, or patients who have exhibited hypersensitivity of PET markers (practical obstacle to the scan)
* Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study
* Severe hepatic impairment
* Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with teriflunomide and thereafter as long as its plasma levels are above 0.02 mg/l.

Minimum Eligible Age

40 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No